SCHEMBL10056023

SCHEMBL10056023

COc1ccc(Cn2c(Nc3ccccc3)nc(=O)n(Cc3ccccc3)c2=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ PROKR1 Q8TCW9 4/20 0.63
▸ P2RX3 P56373 16/20 0.62
▸ PROKR2 Q8NFJ6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10056259 0.98 P2RX3 (0.66) PROKR1P2RX3PROKR2
SCHEMBL10055370 0.90 P2RX3 (0.69) PROKR1P2RX3
SCHEMBL12045896 0.90 P2RX3 (0.64) PROKR1P2RX3PROKR2
SCHEMBL10056263 0.89 P2RX3 (0.68) PROKR1P2RX3PROKR2
SCHEMBL12045892 0.88 P2RX3 (0.63) PROKR1P2RX3
SCHEMBL12046033 0.87 P2RX3 (0.80) P2RX3
SCHEMBL12045898 0.87 P2RX3 (0.80) P2RX3
SCHEMBL12045890 0.83 P2RX3 (0.68) P2RX3
SCHEMBL12046084 0.83 P2RX3 (0.80) P2RX3
SCHEMBL12045897 0.82 P2RX3 (0.61) PROKR1P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718790-B2 Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same SHIONOGI & CO., LTD. (JP) 2017-08-01 — — US disclosed
US-9718790-B2 Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same SHIONOGI & CO., LTD. (JP) 2017-08-01 — — US disclosed
US-9688643-B2 Triazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2017-06-27 — — US disclosed
US-9688643-B2 Triazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2017-06-27 — — US disclosed
US-20160185736-A1 NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. 2016-06-30 — — US disclosed
US-20160185736-A1 NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. 2016-06-30 — — US disclosed
EP-2604595-B1 TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY SHIONOGI & CO (JP) 2016-03-16 — — EP disclosed
US-9150546-B2 Triazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2015-10-06 — — US disclosed
US-9150546-B2 Triazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2015-10-06 — — US disclosed
WO-2012020749-A1 TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY 塩野義製薬株式会社 (JP) 2012-02-16 — — WO disclosed
US-20110319414-A1 NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2011-12-29 — — US disclosed
US-20110319414-A1 NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185736-A1 NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX5, P2RX2 PROKR1 1163/4885P2RX3 1/4885PROKR2 1259/4885
US-20110319414-A1 NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX5, P2RX2 PROKR1 1270/4885P2RX3 1/4885PROKR2 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback